CPHI 2025: directing AI-driven innovation to harness Europe’s data edge
At the 2025 CPHI conference, Montserrat Dabban from Biocat emphasized the importance of AI-driven innovation in the European biopharma industry. She urged stakeholders to leverage health data to tackle challenges like treatment resistance, drug affordability, and patent expiries. Dabban highlighted the need for collaboration in addressing issues such as aging populations and antimicrobial resistance, advocating for improved data utilization from wearable devices and adaptive trials. She concluded that AI is essential for processing health data to enhance clinical trials and foster breakthroughs in the industry.
Europe’s biopharma stakeholders should seek innovation through AI to meet the challenges of treatment resistance, drug affordability, and a creeping patent cliff, channelling the continent’s health data to catch up to more competitive industries in the US and China.
This was the view Montserrat Dabban outlined in her keynote address at the 2025 CPHI conference, which took place on 28–30 October in Frankfurt. Dabban is the director of strategic foresight and international relations at Biocat, a public-private entity to support the healthcare ecosystem in Catalonia, Spain.
Go deeper with GlobalData
ReportsSmart Pharma - Thematic Research
- Reports
Artificial Intelligence (AI) in Healthcare - Thematic Research
Go deeper with GlobalData
The gold standard of business intelligence.
Find out more
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
She said that stakeholders in the European biopharma industry could find innovative solutions to challenges in several key areas by using AI to leverage the vast amounts of data collected by health systems for drug discovery and improved trial design.
Dabban identified several key challenges faced by the global biopharma industry today, including logistical ones like scaling up cell and gene therapies, improving clinical trial speeds, drug affordability, as well as the uncertainties of supply chain resilience, sustainability, and pandemic preparedness.
Meanwhile, she noted the industry faces an oncoming wave of drug patent expiries, risking billions of dollars in total annual revenues: “Pipelines are thinning … pipeline growth slowed.”
Additionally, current research trends have a lopsided focus on development in metabolic, immunological, and oncological diseases at the expense of other indications.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTo avoid the pitfalls of what Dabban termed “therapeutic saturation” — too many molecules developed for too few targets — she said all stakeholders in European biopharma must cooperate in addressing several key domains: aging populations, brain health, cancer, antimicrobial resistance, health equity, and rare disease. To do so, she pointed to upscaling the utilisation of Europe’s extensive health databases.
Dabban said that improved use of data from wearable devices can open the door to digital phenotyping, improved biomarkers, and centralised endpoints in neurological trials. For example, in oncology, she suggested exploring adaptive trials and federated analytics so that data from multiple sources can be analysed without needing to be centralised.
But Dabban told attendees that a vast data store was “useless if it’s not processed, and we need technology for that”. Hence, AI would prove key to effectively processing health data as a means to developing faster clinical trials with more focussed endpoints, she said.
“We are at a crossroads. We have to seize the moment for Europe … we have to expect more competition, but also more breakthroughs,” Dabban concluded.
Pharmaceutical Technology Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate Now